Australia's pharmaceutical cost sharing policy: reducing waste or affordability?

Australian Health Review

Volumn 33, Issue 2, 2009, Pages 231-240

  Doran, Evan ^a   Robertson, Jane ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66749091605     PISSN: 01565788     EISSN: 14498944     Source Type: Journal    
DOI: 10.1071/AH090231     Document Type: Article

References (67)

1. Britt H, Miller GC, Charles J, et al. General practice activity in Australia 2007-08. General Practice Series No. 22. Canberra: Australian Institute of Health and Welfare, 2008. (AIHW Cat. No. GEP 22.)
2. Harvey KJ. The Pharmaceutical Benefits Scheme 2003-2004. Australia New Zealand Health Policy [online] 2005; 2 (2). Available at: http://wwwanzhealthpolicy.com/content/2/1/2
3. Murphy K. PBS could well break, warns Costello. The Age (Melbourne) 2006; Apr 27.
4. Sell SK, Prakash A. Using ideas strategically: the contest between business and NGO networks in intellectual property rights. International Studies Quarterly 2004; 48 (1): 143-75.
5. Grund J. The societal value of pharmaceuticals. Balancing industrial and healthcare policy. Pharmacoeconomics 1996; 10 (1): 14-22.
6. Campbell J. Institutional analysis and the role of ideas in political economy. Theory and Society 1998; 27: 377-409.
7. Surel Y. The role of cognitive and normative frames in policy-making. Journal of European Public Policy 2000; 7 (4): 495-512.
8. Yee AS. The causal effects of ideas on policies. International Organization 1996; 50 (1): 69-108.
9. Campbell JL. Ideas, politics and public policy Ann Rev Sociol 2002; 28: 21-38.
10. Hall PA. Policy paradigms, social learning and the state: the case of economic policy making in Britain. Comparative Politics 1993; 25 (3): 275-96.
11. Richardson J. The effects of consumer co-payments in medical care. National Health Strategy Unit, 1991. (National Health Strategy Background Paper No. 5.)
12. Sansom L. The Australian National Medicinal Drug Policy. J Qual Clin Pract 1999; 19: 31-5.
13. Rickard M. The Pharmaceutical Benefits Scheme: options for cost control. Current issues Brief No. 12, 2001-02. Canberra: Department of the Parliamentary Library, Commonwealth of Australia, 2002.
14. Department of Health and Ageing. Expenditure and prescriptions 12 months to 30 June 2007. Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbs-stats-pbexp-jun07
15. Hill SR, Henry DA and Smith AJ. Rising prescription drug costs: whose responsibility? Med J Aust 1997; 167: 6-7.
16. Richardson JRJ, Segal L. Private health insurance and the Pharmaceutical Benefits Scheme: how effective has recent policy been? Aust Health Rev 2004; 28 (1): 34-47. Available at: http://www.aushealthreview.com.au/publications/articles/issues/ahr_28_1_300904/ahr_28_1_034-047.asp
17. Dalton A. Australia's pharmaceutical benefits system: flawed but improving and better than anywhere else. Aust Health Rev 2001; 24 (2): 7-14. Available at: http://www.aushealthreview.com.au/publications/articles/issues/ahr_24_2_010401/ahr_24_2_07-14.asp
18. Goddard M, Henry DA, Birkett D. Securing the future of the Pharmaceutical Benefits Scheme. In: Mooney G, Plant A (eds). Daring to dream: the future of Australian Health Care. Perth: Black Swan Press, 2002.
19. Australian Governmnet Productivity Commission. International pharmaceutical price differences [research report]. Canberra: Ausinfo, 2001. Available at: http://www.pc.gov.au/projects/study/pbsprices/docs/finalreport
20. Richardson JRJ. Priorities of health policy: cost shifting or population health. Australia and New Zealand Health Policy [online] 2005; 2: 1. Available at: http://www.anzhealthpolicy.com/content/2/1/1
21. Henry DA. Prescribing costs: whose responsibility? Aust Prescriber 1997; 20 (2): 26-27.
22. Smith AJ, McGettigan P. Quality use of medicines in the community: the Australian experience. Br J Clin Pharmacol 2000; 50: 515-19.
23. Peabody J, Bickel SR, Lawson J. The Australian health care system: are the incentives down under right side up? JAMA 1996; 276: 1944-50.
24. Australian Governmnet Department of Health and Aged Care. National Medicines Policy 2000. Canberra: Commonwealth of Australia, 1999. Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/nmp-objectives-policy.htm
25. International Monetary Fund. Australia: 2002 Article IV Consultation. Country Report 02/201. IMF, Sep 2002. Available at: http://www.imf.org/external/pubs/ft/scr/2002/cr02201.pdf
26. Nyman JA. Is 'moral hazard' inefficient? Implications of a new theory of health insurance. Health Aff (Millwood) 2004; 23: 194-9.
27. Keeler EB, Rolph JE. How cost sharing reduced medical spending of participants in the health insurance experiment. JAMA 1983; 249: 2220-7.
28. Nelson AA, Reeder C, Dickson WM. The effect of a Medicaid drug copayment program on the utilization and cost of prescription services. Med Care 1984; 22: 724-36.
29. Richardson J. Evidenced based policy: can we move on? Healthcover 1999; 8 (2), 39-41.
30. Thurner PW, Kotzian P. Comparative health care systems: outline for an empirical application of new institutional economics approaches. Paper delivered to the European Consortium for Political Research meeting April 2001, Grenoble. Available at: www.essex.ac.uk/ECPR/events/jointsessions/paperarchive/grenoble/ws15/thurnerkotzian.PDF
31. Pauly MV. Medicare drug coverage and moral hazard. Health Aff (Millwood) 2004; 23 (1): 113.
32. Pauly MV. The truth about moral hazard and adverse selection. Eighteenth Annual Herbert Lourie Memorial Lecture on Health Policy. Briefing Paper 36. Syracuse University, Center for Policy Research, 2007. Available at: http://www-cpr.maxwell.syr.edu
33. Nyman JA. The value of health insurance. In: Jones AM, editor. The Elgar companion to health economics. Cheltenham: Edward Elgar Publishing, 2006: 95-103.
34. Doran E, Henry DA. The PBS community awareness campaign: how helpful is blaming patients? Med J Aust 2003; 179: 544-5.
35. Australian Associated Press. Campaign will hurt the chronically ill: ALP. Sydney Morning Herald 2005: Sep 27.
36. Costello P. Budget Speech 2005-06. Delivered on 10th May 2005 on the Second Reading of the Appropriation Bill (no. 1) 2005-06. Available at: www.budget.gov.au/2005-06/speech/download/speech.pdf
37. Löfgren H. The Pharmaceutical Benefits Scheme and the shifting paradigm of welfare policy. Aust Health Rev 1998; 21 (2): 111-23. Available at: http://www.aushealthreview.com.au/publications/articles/issues/ahr_21_2_010498/ahr_21_2_111-123.asp
38. Sloan C. A history of the Pharmaceutical Benefits Scheme 1947-1992. Canberra: Commonwealth Department of Human Services and Health, 1995.
39. Australian Government Department of Health and Ageing. About the PBS. Available at: http://www.pbs.gov.au/html/consumer/pbs/about#d128741e32 (last accessed 25 January 2009).
40. Medicare Australia. PBS Safety Net. Available at: http://www.medicareaustralia.gov.au/public/services/msn/ (last accessed 25 Jan 2009).
41. Sweeny K. Key aspects of the Australian Pharmaceutical Benefits Scheme. Pharmaceutical Industry Project Working Paper No. 35. Melbourne: Centre for Strategic Economic Studies, Victoria University, 2007.
42. Searles A, Doran E, Faunce TA, Henry D. The affordability of prescription medicines in Australia: good for government poor for patients. Unpublished.
43. Ross B, Snasdell-Taylor J, Cass Y, Azmi S. Health financing in Australia: the objectives and players. Occasional Papers: Health Financing Series, Volume 1. Canberra: Commonwealth Department of Health and Aged Care, 1999.
44. National Commission of Audit. Report to the Commonwealth Government. Canberra: AGPS, Jun 1996. Available at: http://www.finance.gov.au/publications/archive-ofpublications/ncoa/appc.htm
45. Mooney G. Key issues in health economics. Prentice Hall/Harvester, Wheatsheaf, 1992.
46. Smith DG, Kirking DM. Impact of consumer fees on drug utilisation. Pharmacoeconomics 1992; 2 (4): 335-42.
47. Gerdtham U-G, Johannesson M. The impact of user charges on the consumption of drugs. Pharmacoeconomics 1996; 9: 478-83.
48. Freemantle N, Bloor K. Lessons from international experience in controlling pharmaceutical expenditure 1: influencing patients. BMJ 1996; 312: 1469-71.
49. Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. Int J Health Serv 2004; 4: 101-122.
50. Ellison SF, Cockburn I, Griliches Z, et al. Characteristics of demand for pharmaceutical products: an examination of four cephalosporins. The RAND Journal of Economics 1997; 28 (3): 426-46.
51. Ryan M. Agency in health care: lessons for economists from sociologists. American Journal of Economics and Sociology 1994; 53 (2): 207-17.
52. Grootendorst PV. Prescription drug insurance and reimbursement. In: Jones A, editor. The Elgar companion to health economics. Cheltenham: Edward Elgar Publishing, 2006.
53. Zweifel P, Manning WG. Moral hazard and consumer incentives in health care. In: Handbook for health economics (Vol 1; Chapter 8). Culyer AJ, Newhouse JP, eds. Elsevier Science, 2000.
54. Lupton D. Consumerism, reflexivity and the medical encounter. Soc Sci Med 1997; 45: 373-81.
55. Nyman JA. The economics of moral hazard revisited. J Health Econ 1999; 18: 811-24.
56. Braithwaite RS, Rosen AB. Linking cost sharing to value: an unrivalled yet unrealised public health opportunity. Ann Intern Med 2007; 146: 602-05.
57. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and health spending, JAMA 2007; 298: 61-9.
58. Gemmill MC, Thomson S, Mossialos E. What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries. Int J Equity Health [online] 2008; 7: 12. Available at: http://www.equityhealthj.com/content/7/1/12
59. Blomqvist A. Does the economics of moral hazard need to be revisited: a comment on the paper by John Nyman. J Health Econ 2004; 20: 283-8.
60. Doran E, Robertson J, Henry D. Moral hazard and prescription medicine use. Soc Sci Med 2005; 60: 1437-43.
61. Blendon RJ, Schoen C, DesRoches CM, et al. Inequities in health care: a five-country survey. Health Aff (Millwood) 2002; 21: 182-91.
62. Doran E, Robertson J, Rolfe I, Henry D. Patient copayments and use of prescription medicines. Aust N Z J Public Health 2004; 28 (1) 62-7.
63. Schoen C, Osborn R, Huynh PT, et al.Taking the pulse of health care systems: experiences of patients with health problems in six countries. Health Aff (Millwood) 2005; 24: 509-25.
64. Hunter Valley Research Foundation. Wellbeing Watch 2006. Newcastle: HVRF, 2006. Available at: http://www.hvrf.com.au/pages/design/links/uploaded/wellbeing%20watch%202006%20final.pdf
65. Davis K, Schoen C, Schoenbaum SC, et al. Mirror, mirror on the wall: an international update on the comparative performance of American health care. New York: Commonwealth Fund, 2007. Available at: http://www.commonwealthfund.org/publications/publications_show.htm?doc_id=48678
66. Hynd A, Roughead EE, Preen DB, et al. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf 2008; 17: 1091-9.
67. Quiggin J. Globalization and economic sovereignty. J Political Philosophy 2001; 9 (1): 56-80.